AIMS: To assess the impact of drug-eluting stents (DES) compared to bare-metal stents (BMS) for the endovascular treatment of @entity2791 ( @entity2791 ). METHODS AND RESULTS: We retrospectively evaluated all of our endovascular BMS- and DES-implantations performed in de- novo @entity2791 between 2000-2014 at our institution. The occurrence of in-stent @entity256 (ISR) detected by ultrasound or angiography, kidney function, blood pressure (BP), and the number of antihypertensive drugs were analyzed as endpoints. Overall, 338 renal arteries were treated in 298 @entity1 . BMS were implanted in 163 (48%), and DES in 175 lesions (52%). Of the 175 lesions treated with DES, 55 (31%) were treated with a BMS-in- DES hybrid-technique. For reasons of comparability, only lesions treated with balloon-sizes of 4-6.5mm were included in the final analysis. After 12 months, the rate of ISR>50% was 18.6% in the BMS- and 7.2% in the DES-group (p=0.031). None of the BMS-in-DES-treated (hybrid) lesions developed ISR (hybrid-technique vs. BMS-only p=0.008, hybrid-technique vs. DES-only p=0.034). Systolic BP and number of antihypertensive drugs remained unchanged in the BMS-group but declined in the DES-group (p=0.02). @entity177 in the BMS-group (p=0.03) but did not change significantly in the DES-group (p=0.188). CONCLUSIONS: DES was superior to BMS in preventing ISR. Overall the BMS-in-DES-technique (hybrid) achieved the lowest risk for ISR.

Drug-eluting stents versus bare-metal stents for the prevention of XXXX in @entity1 with renovascular disease.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity177 :: ('MESH:D051437', 'Disease') :: ['Renal function significantly deteriorated'] @entity2791 :: ('MESH:D012078', 'Disease') :: ['ARAS', 'atherosclerotic renal artery stenosis'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']
@entity256 :: (MESH:D023903,Disease) :: ['restenosis']
